Stereotaxis (STXS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
3 Apr, 2026Executive summary
Annual meeting scheduled for May 14, 2026, at 10:00 AM CDT at the principal executive offices in St. Louis, MO.
Shareholders can vote online, by phone, mail, or in person until May 13, 2026, 11:59 PM ET.
Proxy materials, including the Notice, Proxy Statement, and Form 10-K, are available online and by request.
Voting matters and shareholder proposals
Election of three Class I directors (David Benfer, Arun Menawat, Myriam Curet) for terms expiring at the 2029 Annual Meeting.
Ratification of Ernst & Young, LLP as independent registered public accounting firm for fiscal year 2026.
Advisory (non-binding) vote to approve executive compensation.
Proxies may vote on other business as may properly come before the meeting.
Board of directors and corporate governance
Board recommends voting FOR all director nominees, auditor ratification, and executive compensation proposals.
Proxy holders appointed with full powers to act and substitute at the meeting.
Latest events from Stereotaxis
- Recurring revenue surged 270% on new catheter adoption, with profitability targeted for early 2027.STXS
Q2 2026 - Resale registration for 108M+ shares highlights dilution and integration risks after Robocath deal.STXS
Registration filing - Registers 19.9% of shares for resale post-Robocath acquisition; no proceeds to company.STXS
Registration filing - Robotic magnetic navigation and digital innovation drive safer, scalable endovascular surgery worldwide.STXS
Investor presentation - Regulatory wins, new products, and Robocath deal drive optimism for double-digit 2026 growth.STXS
Q1 2026 - Acquisition accelerates robotic leadership in endovascular care, targeting rapid market growth.STXS
M&A announcement - Annual meeting to elect directors, ratify auditor, and approve executive compensation.STXS
Proxy filing - Shelf registration enables up to $150 million in offerings to fund growth, with significant dilution risk.STXS
Registration Filing - Q1 2025 revenue up 9% to $7.5M, driven by recurring revenue and innovation, despite higher net loss.STXS
Q1 2025